Cocrystal Pharma Completes Phase 1b Trial for Norovirus Antiviral CDI-988
Event summary
- Cocrystal Pharma dosed the last subject in its Phase 1b norovirus challenge study for CDI-988, an oral antiviral candidate.
- The study, conducted at Emory University, is evaluating CDI-988's efficacy in preventing and treating norovirus infections.
- No serious adverse events were reported in the trial, with preliminary efficacy results expected by early 2027.
- CDI-988 is designed to inhibit viral replication across all known norovirus strains.
The big picture
Norovirus remains a significant unmet medical need, with an estimated 685 million global cases annually and a $60 billion economic impact. Cocrystal's CDI-988 represents one of the first direct-acting antivirals specifically targeting norovirus, positioning the company at the forefront of a potential new therapeutic class. The successful completion of this Phase 1b trial is a critical step in validating the clinical potential of CDI-988 and addressing the substantial burden norovirus imposes on healthcare systems worldwide.
What we're watching
- Regulatory Pathway
- How the efficacy and safety data from this study will shape CDI-988's regulatory approval process.
- Market Potential
- Whether CDI-988 can capture significant market share in the $60 billion global norovirus treatment space.
- Clinical Advancement
- The pace at which Cocrystal can progress CDI-988 into later-stage clinical trials based on the preliminary results.
Related topics